Total and high molecular weight adiponectin concentrations in plasma of patients with end-stage renal disease before and after peritoneal dialysis.

BACKGROUND

Adiponectin is an antiatherogenic adipocyte-derived proteins. The level of plasma adiponectin is inversely correlated to cardiovascular risk in patients with end-stage renal disease (ESRD). The aim of this study was to elucidate the changes of adiponectin concentrations in newly diagnosed ESRD patients after peritoneal dialysis.

METHODS

In 16 newly diagnosed ESRD patients, total concentrations of adiponectin and high molecular weight (HMW) adiponectin, the HMW ratio (HMWR; ratio of the plasma level of HMW adiponectin to that of total adiponectin), the body mass index (BMI), insulin concentrations, blood glucose and estimation of the insulin sensitivity index by the homeostasis model assessment (HOMR(IR)) were compared before and after 1 year of peritoneal dialysis.

RESULTS

Plasma total adiponectin was decreased from 15.52 +/- 9.35 microg/mL to 11.80 +/- 6.84 microg/mL (P = 0.046), HMW adiponectin was decreased from 9.05 +/- 6.48 microg/mL to 4.83 +/- 4.15 microg/mL (P = 0.009), and HMWR was decreased from 0.51 +/- 0.18 to 0.35 +/- 0.20 (P = 0.008). Total and HMW adiponectin/BMI ratio was decreased. The BMI was increased from 25.2 +/- 5.7 to 25.8 +/- 6.2 (P = 0.036). The HOMR(IR), insulin level and lipid profile were not changed.

CONCLUSION

Total adiponectin, HMW adiponectin and HMWR were decreased in newly diagnosed ESRD patients after 1 year of peritoneal dialysis. The factors that influence the decrease of the level of adiponectin should be studied in a larger prospective study.